NCT07479446 Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery
| NCT ID | NCT07479446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | PONV |
| Study Type | INTERVENTIONAL |
| Enrollment | 174 participants |
| Start Date | 2026-03-25 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 174 participants in total. It began in 2026-03-25 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-center, double-blind, randomized controlled trial aims to determine whether oliceridine for patient-controlled intravenous analgesia (PCIA) can significantly reduce the incidence of postoperative nausea, an opioid-related adverse reaction, compared to sufentanil PCIA in patients undergoing cerebellopontine angle (CPA) region surgery. A secondary objective is to compare the postoperative analgesic effects between the two drugs. The study plans to enroll 174 patients (with a calculated sample size of 164 plus 5% for attrition). The primary outcome is the incidence of nausea within 6-48 hours postoperatively. Secondary outcomes include pain scores at rest and during movement within 48 hours, and other exploratory outcomes such as vomiting incidence, time to first flatus/defecation, and gastrointestinal function scores.
Eligibility Criteria
Inclusion Criteria: * Scheduled for elective CPA region surgery with planned PCIA. * Age 18-65 years. * ASA physical status I-III. * Provides written informed consent. Exclusion Criteria: * Opioid tolerance (taking opioids ≥1 week, equivalent to oral morphine ≥50 mg/day or oxycodone ≥30 mg/day). * Severe cardiopulmonary, hepatic, renal, vascular, neurological, hematological, gastrointestinal, or endocrine diseases. * Postoperative ICU admission with tracheal intubation. * BMI ≤18.5 or ≥30 kg/m². * Participation in another clinical trial within 3 months prior to screening.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07479446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying PONV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07479446 currently recruiting?
Yes, NCT07479446 is actively recruiting participants. Contact the research team at kitten15@126.com for enrollment information.
Where is the NCT07479446 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07479446 clinical trial?
NCT07479446 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 174 participants.